EUVIMEDEUVIMED entdecken
Crossref

Dual Barrier‐Penetrating Inhaled Nanoparticles for Enhanced Idiopathic Pulmonary Fibrosis Therapy

Ming‐Yuan Yang, Meng‐Meng Han, Ling Tang, Yu‐Yang Bi, Xue‐Na Li, Jee‐Heon Jeong, Yi Wang, Hu‐Lin Jiang

Advanced Functional Materials · 2024-06 · 34 (23)

DOI: 10.1002/adfm.202315128 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Functional Materials, online erschienen am 14.02.2024. Verfasst von Ming‐Yuan Yang und 7 weiteren Autor:innen. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: National Basic Research Program of China, National Natural Science Foundation of China, Natural Science Foundation of Jiangsu Province.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Idiopathic pulmonary fibrosis (IPF) is an age‐related pulmonary interstitial disease with unclear etiology that poses a serious threat to human health. IPF interventions in clinical settings mainly involve oral medications, such as nintedanib (NIN), which exhibit limited accumulation in the lungs and neglect the epithelial micro‐environment. Inhalation is an efficient route for the treatment of pulmonary diseases. However, the mucus barrier in the trachea and the extracellular matrix (ECM) barrier in the interstitium are the two main obstacles to inhaled therapeutic agent delivery. Therefore, in this study, dual barrier‐penetrating inhaled liposomes (AN‐TR) are constructed utilizing tris‐(2‐carboxyethyl)‐phosphine (TCEP) and l ‐arginine to penetrate the mucus and ECM barriers, respectively. This approach facilitates the thorough and uniform distribution of NIN and navitoclax (ABT‐263) across all five lung lobes. Furthermore, ABT‐263 can remove the senescent epithelial cells in the trachea and alveoli, thereby improving the efficiency of NIN for IPF treatment. This study suggests dual barrier‐penetrating inhaled liposomes as efficient noninvasive vehicles for first‐line clinical medications to improve the efficacy of IPF treatment.

Förderung

  • National Basic Research Program of China
  • National Natural Science Foundation of China
  • Natural Science Foundation of Jiangsu Province

Zitieren

APA

Yang, M., Han, M., Tang, L., Bi, Y., Li, X., Jeong, J., Wang, Y., & Jiang, H. (2024). Dual Barrier‐Penetrating Inhaled Nanoparticles for Enhanced Idiopathic Pulmonary Fibrosis Therapy. Advanced Functional Materials, 34(23). https://doi.org/10.1002/adfm.202315128

Vancouver

Yang M, Han M, Tang L, Bi Y, Li X, Jeong J, et al. Dual Barrier‐Penetrating Inhaled Nanoparticles for Enhanced Idiopathic Pulmonary Fibrosis Therapy. Advanced Functional Materials. 2024;34(23). doi:10.1002/adfm.202315128

BibTeX
@article{Yang2024,
  author = {Yang, Ming‐Yuan and Han, Meng‐Meng and Tang, Ling and Bi, Yu‐Yang and Li, Xue‐Na and Jeong, Jee‐Heon and Wang, Yi and Jiang, Hu‐Lin},
  title = {Dual Barrier‐Penetrating Inhaled Nanoparticles for Enhanced Idiopathic Pulmonary Fibrosis Therapy},
  journal = {Advanced Functional Materials},
  year = {2024},
  volume = {34},
  number = {23},
  doi = {10.1002/adfm.202315128}
}
Kostenlos starten →